Previous 10 | Next 10 |
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s research into efficacy of bempedoic acid in patients wi...
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24 th , 2022. A ...
Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue. The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year. Esperion had a 32% year-over-year cost savings of the company operating expenses compared ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Esperion Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Esperion Therapeutics, Inc. (ESPR) Q1 2022 Earnings Conference Call May 3, 2022 08:00 ET Company Participants Tiffany Aldrich - Senior Manager, Corporate Communications Sheldon Koenig - President and Chief Executive Officer Joanne Foody - Chief Medical Officer Eric Warren - Chief Commercial O...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q1 2022 Earnings Call May 03, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q1 2022 Earnings Call Transcript
Esperion (NASDAQ:ESPR) stock rose May 3 after Q1 results beat analysts' estimates. Q1 total revenues increased +136% Y/Y to ~$18.84M Y/Y. U.S. net product revenue of cholesterol lowering therapies Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid and ezetimibe) tablets...
Esperion Therapeutics press release (NASDAQ:ESPR): Q1 GAAP EPS of -$0.93 beats by $0.11. Revenue of $18.83M (+135.4% Y/Y) beats by $3.42M. For further details see: Esperion Therapeutics GAAP EPS of -$0.93 beats by $0.11, revenue of $18.83M beats by $3.42M
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.04 (+70.3% Y/Y) and the consensus Revenue Estimate is $15.41M (+92.6% Y/Y). Over the last 1 year, ESPR has beaten EPS estimates 25% of th...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ...
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consens...